| 1 |
35209965 | Enhanced antitumor efficacy by combining afatinib with MDV3100 in castration-resistant prostate cancer. | 2022 Feb 1 |
1 |
| 2 |
34188489 | Identification of Phospho-Tyrosine Targets as a Strategy for the Treatment of Esophageal Adenocarcinoma Cells. | 2021 |
1 |
| 3 |
31359792 | Knockdown of lncRNA BLACAT1 reverses the resistance of afatinib to non-small cell lung cancer via modulating STAT3 signalling. | 2020 Mar |
1 |
| 4 |
32269717 | Concurrent inhibition of ErbB family and MEK/ERK kinases to suppress non-small cell lung cancer proliferation. | 2020 |
1 |
| 5 |
31285959 | Inhibition of cisplatin-resistant head and neck squamous cell carcinoma by combination of Afatinib with PD0325901, a MEK inhibitor. | 2019 |
1 |
| 6 |
29430509 | Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. | 2018 Jan 20 |
1 |
| 7 |
29959202 | Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer. | 2018 Sep |
2 |
| 8 |
30057690 | HER3 signaling and targeted therapy in cancer. | 2018 Jan 30 |
1 |
| 9 |
30740589 | NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells. | 2018 Jun |
1 |
| 10 |
28938595 | Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement. | 2017 Aug 29 |
1 |
| 11 |
26668065 | Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status. | 2016 Jun |
2 |
| 12 |
26934000 | The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. | 2016 Apr 12 |
5 |
| 13 |
27044931 | Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. | 2016 Jun 20 |
2 |
| 14 |
27080337 | Afatinib Is Active in Platinum-Refractory ERBB-Mutant Urothelial Carcinoma. | 2016 Jun |
1 |
| 15 |
26123538 | Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. | 2015 Jun |
1 |
| 16 |
26296355 | Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas. | 2015 Dec 15 |
1 |
| 17 |
26418897 | The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. | 2015 Oct 20 |
3 |
| 18 |
24435321 | Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. | 2014 Feb |
1 |
| 19 |
24646054 | Afatinib for the treatment of advanced non-small-cell lung cancer. | 2014 Apr |
1 |
| 20 |
24754585 | LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer. | 2014 Mar |
1 |
| 21 |
25489260 | Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. | 2014 Dec |
1 |
| 22 |
23816254 | A gene expression profile indicative of early stage HER2 targeted therapy response. | 2013 Jul 1 |
1 |
| 23 |
21617858 | Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. | 2011 Aug |
1 |